Head to head
Rapamycin plus acarbose against Rapamycin
One of the few longevity combinations tested as a combination rather than assembled by a clinic, in mice, where the pair outperformed either drug alone. Everything about the result is rodent and none of it has been tested in people.
Column A
Rapamycin plus acarboseRapamycin plus acarbose (Interventions Testing Program combination arm, RaAc)
Started at 9 months, rapamycin 14.7 ppm plus acarbose 1,000 ppm extended median mouse lifespan 28 percent in females and 34 to 37 percent in males, the largest pooled effect the Interventions Testing Program has published, and worked at all three sites in both sexes. In males it exceeded historical rapamycin-alone cohorts; in females it did not. No human has taken the two together in any study.
Column B
RapamycinRapamycin (Sirolimus, mTOR inhibitor)
An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity.
Side by side, on the facts we can check
| Attribute | Rapamycin plus acarbose | Rapamycin |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Both drugs are FDA-approved for other indications (sirolimus for transplant rejection and other uses; acarbose for type 2 diabetes). The combination is not approved for anything and has never been given to people in a study. The lifespan result is in mice and the comparison to single drugs is historical, not contemporaneous. | FDA-approved (Rapamune); longevity use is off-label and investigational |
| Half-life | Not reported | ~60 hours |
| Molecular weight | Not reported | 914.2 Da |
| Mechanism | Rapamycin inhibits mTORC1; acarbose inhibits intestinal alpha-glucosidases and blunts the post-meal glucose rise, with much of its systemic effect thought to run through altered gut fermentation and microbiome. The ITP combined them because they act on different nutrient-sensing inputs, because acarbose might offset the glucose intolerance rapamycin causes in mice, and because each had replicated on its own. Later ITP-adjacent work found that rapamycin, acarbose and 17-alpha-estradiol converge on shared downstream changes in liver signalling, and that acarbose or rapamycin started at 4 or 16 months each improve rotarod performance and reduce cardiac hypertrophy in aged mice, with acarbose having the larger effect on the cardiac lipidome. None of that has been measured in a person taking both drugs, and the human pharmacology of each is on its own page. | Inhibits the mTOR pathway, mimicking aspects of caloric restriction and enhancing autophagy and cellular maintenance. |
| Human studies cited | 0 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved (for its labeled use), prescription only |
Frequently asked questions
What is the difference between Rapamycin plus acarbose and Rapamycin?
Rapamycin plus acarbose: Started at 9 months, rapamycin 14.7 ppm plus acarbose 1,000 ppm extended median mouse lifespan 28 percent in females and 34 to 37 percent in males, the largest pooled effect the Interventions Testing Program has published, and worked at all three sites in both sexes. In males it exceeded historical rapamycin-alone cohorts; in females it did not. No human has taken the two together in any study. Rapamycin: An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity.
Which has stronger research evidence, Rapamycin plus acarbose or Rapamycin?
This database does not grade compounds. It counts what was run in people: 0 of the 7 studies cited on the Rapamycin plus acarbose profile were human work, against 2 of 3 for Rapamycin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Rapamycin plus acarbose and Rapamycin FDA-approved?
Rapamycin plus acarbose: Both drugs are FDA-approved for other indications (sirolimus for transplant rejection and other uses; acarbose for type 2 diabetes). The combination is not approved for anything and has never been given to people in a study. The lifespan result is in mice and the comparison to single drugs is historical, not contemporaneous.. Rapamycin: FDA-approved (Rapamune); longevity use is off-label and investigational.
Related posts
Blog articles that cover Rapamycin plus acarbose or Rapamycin, newest first.
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 8, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 8, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.